Extracellular Vesicles and Carried miRNAs in the Progression of Renal Cell Carcinoma.
Biomarkers
Cancer-Associated Fibroblasts
/ metabolism
Carcinoma, Renal Cell
/ genetics
Circulating MicroRNA
Disease Progression
Extracellular Vesicles
/ metabolism
Humans
Kidney Neoplasms
/ genetics
MicroRNAs
/ genetics
Neoplastic Stem Cells
/ metabolism
Neovascularization, Pathologic
/ genetics
Stromal Cells
/ metabolism
Tumor Microenvironment
/ genetics
exosomes
metastasis
microRNAs
renal cancer stem cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Apr 2019
13 Apr 2019
Historique:
received:
26
03
2019
revised:
10
04
2019
accepted:
11
04
2019
entrez:
25
4
2019
pubmed:
25
4
2019
medline:
10
8
2019
Statut:
epublish
Résumé
The formation and maintenance of renal cell carcinomas (RCC) involve many cell types, such as cancer stem and differentiated cells, endothelial cells, fibroblasts and immune cells. These all contribute to the creation of a favorable tumor microenvironment to promote tumor growth and metastasis. Extracellular vesicles (EVs) are considered to be efficient messengers that facilitate the exchange of information within the different tumor cell types. Indeed, tumor EVs display features of their originating cells and force recipient cells towards a pro-tumorigenic phenotype. This review summarizes the recent knowledge related to the biological role of EVs, shed by renal tumor cells and renal cancer stem cells in different aspects of RCC progression, such as angiogenesis, immune escape and tumor growth. Moreover, a specific role for renal cancer stem cell derived EVs is described in the formation of the pre-metastatic niche. We also highlight the tumor EV cargo, especially the oncogenic miRNAs, which are involved in these processes. Finally, the circulating miRNAs appear to be a promising source of biomarkers in RCC.
Identifiants
pubmed: 31013896
pii: ijms20081832
doi: 10.3390/ijms20081832
pmc: PMC6514717
pii:
doi:
Substances chimiques
Biomarkers
0
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 16973
Références
Nature. 1999 May 20;399(6733):271-5
pubmed: 10353251
Cancer Res. 2000 Apr 1;60(7):1942-8
pubmed: 10766184
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
FEBS Lett. 2004 Nov 19;577(3):439-45
pubmed: 15556624
J Clin Oncol. 2005 Apr 20;23(12):2763-71
pubmed: 15837991
Dev Biol. 2007 Feb 1;302(1):1-12
pubmed: 16989803
FASEB J. 2008 Oct;22(10):3696-705
pubmed: 18614581
Am J Physiol Renal Physiol. 2008 Sep;295(3):F680-7
pubmed: 18614618
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Tissue Antigens. 2008 Aug;72(2):137-48
pubmed: 18721274
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3794-9
pubmed: 19234131
EMBO Rep. 2009 Apr;10(4):400-5
pubmed: 19247375
Lancet. 2009 Mar 28;373(9669):1119-32
pubmed: 19269025
Lab Invest. 2009 May;89(5):597-606
pubmed: 19290006
Lab Invest. 2009 Nov;89(11):1317-28
pubmed: 19786948
Exp Lung Res. 2009 Oct;35(8):646-64
pubmed: 19895320
J Urol. 2010 Feb;183(2):743-51
pubmed: 20022054
Transl Oncol. 2010 Apr;3(2):109-13
pubmed: 20360935
Biochem Biophys Res Commun. 2010 Apr 30;395(2):275-80
pubmed: 20381459
Eur Respir J. 2011 Mar;37(3):617-23
pubmed: 20595154
Hepatology. 2010 Sep;52(3):1164-6
pubmed: 20812359
Cancer Lett. 2010 Dec 28;299(2):150-60
pubmed: 20846785
Int J Oncol. 2011 Jan;38(1):97-103
pubmed: 21109930
Cancer Res. 2011 Apr 15;71(8):2926-37
pubmed: 21393507
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
Ther Adv Med Oncol. 2010 May;2(3):209-19
pubmed: 21789135
PLoS One. 2011;6(9):e25787
pubmed: 21984948
J Cancer. 2011;2:515-26
pubmed: 22043236
Cancer Biomark. 2010;9(1-6):461-73
pubmed: 22112490
J Transl Med. 2012 Mar 22;10:55
pubmed: 22440013
PLoS One. 2012;7(4):e34608
pubmed: 22511954
Cancer Epidemiol. 2012 Aug;36(4):391-4
pubmed: 22542158
Cancer Lett. 2013 Sep 10;338(1):141-6
pubmed: 22587951
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Innate Immun. 2013 Feb;19(1):98-111
pubmed: 22732734
J Surg Oncol. 2013 Feb;107(2):105-10
pubmed: 22767438
Curr Mol Med. 2013 Jan;13(1):58-67
pubmed: 22834836
Exp Mol Pathol. 2013 Feb;94(1):115-20
pubmed: 23064048
Gene. 2013 Sep 15;527(1):26-32
pubmed: 23791657
Cell Transplant. 2014;23(9):1111-25
pubmed: 23849060
Urol Int. 2013;91(3):363-9
pubmed: 23921176
J Extracell Vesicles. 2013 Feb 15;2:null
pubmed: 24009890
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Genes Chromosomes Cancer. 2014 Jan;53(1):38-51
pubmed: 24166983
Int Urol Nephrol. 2014 May;46(5):915-20
pubmed: 24202958
Int J Oncol. 2014 Jan;44(1):53-8
pubmed: 24212760
J Cell Physiol. 2014 Jul;229(7):916-26
pubmed: 24318462
Tumour Biol. 2014 May;35(5):4057-66
pubmed: 24379138
Mol Clin Oncol. 2013 Mar;1(2):235-240
pubmed: 24649153
Front Oncol. 2014 Mar 17;4:49
pubmed: 24672771
Cell. 2014 Mar 27;157(1):77-94
pubmed: 24679528
Biochem Biophys Res Commun. 2014 Sep 12;452(1):163-9
pubmed: 25152390
Front Immunol. 2014 Aug 11;5:382
pubmed: 25157253
Eur Urol. 2015 Mar;67(3):519-30
pubmed: 25449206
Sci Rep. 2015 Jan 05;5:7610
pubmed: 25556603
Curr Drug Targets. 2015;16(2):125-35
pubmed: 25619751
Oncotarget. 2015 Apr 10;6(10):7959-69
pubmed: 25797265
Oncogene. 2015 Nov 26;34(48):5857-68
pubmed: 25867073
Am J Pathol. 2015 Jul;185(7):1991-9
pubmed: 25956032
Oncol Rep. 2015 Aug;34(2):739-46
pubmed: 26058752
Int J Mol Sci. 2015 Sep 29;16(10):23382-9
pubmed: 26426010
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):183-94
pubmed: 26558360
Int J Mol Sci. 2015 Dec 08;16(12):29219-25
pubmed: 26670229
Oncotarget. 2016 Jan 26;7(4):3993-4008
pubmed: 26675257
Cancers (Basel). 2015 Dec 18;7(4):2466-85
pubmed: 26694467
BMC Cancer. 2015 Dec 24;15:1009
pubmed: 26704308
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
Mol Cancer. 2016 May 17;15(1):39
pubmed: 27189224
Immunotargets Ther. 2013 Jul 22;2:73-90
pubmed: 27471690
Oncotarget. 2016 Oct 4;7(40):65862-65875
pubmed: 27588469
J Cancer Res Clin Oncol. 2017 Jan;143(1):95-104
pubmed: 27638770
Oncotarget. 2016 Nov 29;7(48):78433-78447
pubmed: 27738339
Int J Oncol. 2016 Dec;49(6):2589-2599
pubmed: 27779660
Cancer Biomark. 2017;18(1):79-85
pubmed: 27814278
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Semin Oncol. 2016 Oct;43(5):566-574
pubmed: 27899189
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Oncotarget. 2017 Feb 7;8(6):9899-9910
pubmed: 28038441
Mol Cancer. 2017 Feb 1;16(1):28
pubmed: 28148265
J Cell Biochem. 2017 Oct;118(10):3424-3434
pubmed: 28322459
Oncogene. 2017 Aug 24;36(34):4929-4942
pubmed: 28436951
Int J Cancer. 2017 Nov 1;141(9):1730-1740
pubmed: 28639257
Eur Urol Focus. 2018 Apr;4(3):412-419
pubmed: 28753793
Biochem Biophys Res Commun. 2017 Oct 21;492(3):356-361
pubmed: 28851650
CA Cancer J Clin. 2017 Nov;67(6):507-524
pubmed: 28961310
Int J Cancer. 2018 Feb 1;142(3):607-617
pubmed: 28975613
Methods Mol Biol. 2018;1692:1-16
pubmed: 28986882
Int J Mol Med. 2017 Dec;40(6):1624-1630
pubmed: 29039606
Oncotarget. 2017 Aug 24;8(42):72835-72846
pubmed: 29069829
Clin Epigenetics. 2018 Jan 23;10:11
pubmed: 29410711
J Pathol Clin Res. 2018 Jan 17;4(1):3-18
pubmed: 29416873
PLoS One. 2018 Feb 23;13(2):e0192790
pubmed: 29474434
Oncol Lett. 2018 Apr;15(4):6003-6008
pubmed: 29552228
Clin Lab. 2018 Apr 1;64(4):569-576
pubmed: 29739083
Cancer Lett. 2018 Sep 1;431:11-21
pubmed: 29800684
Oncol Lett. 2018 Aug;16(2):2326-2334
pubmed: 30008936
NPJ Breast Cancer. 2018 Jul 16;4:18
pubmed: 30038960
Int J Mol Sci. 2018 Aug 26;19(9):null
pubmed: 30149673
Biochimie. 2019 Jan;156:69-78
pubmed: 30296465
J Cancer Res Clin Oncol. 2019 Jan;145(1):153-163
pubmed: 30368665
Cent European J Urol. 2018;71(3):295-303
pubmed: 30386650
Surg Pathol Clin. 2018 Dec;11(4):797-812
pubmed: 30447842
J Cell Biochem. 2019 Mar;120(3):2954-2963
pubmed: 30537206
Histopathology. 2019 Jan;74(1):18-30
pubmed: 30565307
Nat Commun. 2018 Dec 19;9(1):5395
pubmed: 30568162
Cancer Biomark. 2019;24(2):153-158
pubmed: 30689558
Oncol Res Treat. 2019;42(3):128-135
pubmed: 30799404
Front Oncol. 2019 Feb 21;9:82
pubmed: 30847298
Exp Mol Med. 2019 Mar 15;51(3):29
pubmed: 30872568
Front Immunol. 2019 Feb 28;10:202
pubmed: 30873152